Advertisement

Erythropoietic therapy in the practice of oncology

  • John Glaspy
Part of the Milestones in Drug Therapy MDT book series (MDT)

Keywords

Darbepoetin Alfa Recombinant Human Erythropoietin Erythropoietic Agent Erythropoietic Therapy Trans Fusion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Groopman JE, Itri LM (1999) Chemotherapy-induced anemia in adults: Incidence and treatment. J Natl Cancer Inst 91: 1616–1634CrossRefPubMedGoogle Scholar
  2. 2.
    Miller CB, Jones RJ, Piantadosi S, Abeloff MD, Spivak JL (1990) Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 322: 1689–1692PubMedGoogle Scholar
  3. 3.
    Means RT Jr Krantz SB (1992) Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 80: 1639–1647PubMedGoogle Scholar
  4. 4.
    Storring PL, Tiplady RJ, Gaines Das RE, Stenning BE, Lamikanra A, Rafferty B, Lee J (1998) Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties. Br J Haematol 100: 79–89PubMedGoogle Scholar
  5. 5.
    Egrie JC, Browne JK (2001) Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 84: 3–10CrossRefPubMedGoogle Scholar
  6. 6.
    Henry DH, Abels RI (1994) Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: Results of double-blind and open-label follow-up studies. Semin Oncol 21: 21–28PubMedGoogle Scholar
  7. 7.
    Ludwig H, Sundal E, Pecherstorfer M, Leitgeb C, Bauernhofer T, Beinhauer A, Samonigg H, Kappeler AW, Fritz E (1995) Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy. Cancer 76: 2319–2329PubMedGoogle Scholar
  8. 8.
    Smith DH, Goldwasser E, Vokes EE (1991) Serum immunoerythropoietin levels in patients with cancer receiving cisplatin-based chemotherapy. Cancer 68: 1101–1105PubMedGoogle Scholar
  9. 9.
    Wood PA, Hrushesky WJ (1995) Cisplatin-associated anemia: An erythropoietin deficiency syndrome. J Clin Invest 95: 1650–1659PubMedGoogle Scholar
  10. 10.
    Platanias LC, Miller CB, Mick R, Hart RD, Ozer H, McEvilly JM, Jones RJ, Ratain MJ (1991) Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients. J Clin Oncol 9: 2021–2026PubMedGoogle Scholar
  11. 11.
    Miller CB, Platanias LC, Mills SR, Zahurak ML, Ratain MJ, Ettinger DS, Jones RJ (1992) Phase I–II trial of erythropoietin in the treatment of cisplatin-associated anemia. J Natl Cancer Inst 84: 98–103PubMedGoogle Scholar
  12. 12.
    Tsukuda M, Mochimatsu I, Nagahara T, Kokatsu T, Sawaki S, Kubota A, Furkawa M, Arai Y (1993) Clinical application of recombinant human erythropoietin for treatments in patients with head and neck cancer. Cancer Immunol Immunother 36: 52–56CrossRefPubMedGoogle Scholar
  13. 13.
    Glimelius B, Linne T, Hoffman K, Larsson L, Svensson JH, Nasman P, Svensson B, Helmers C (1998) Epoetin beta in the treatment of anemia in patients with advanced gastrointestinal cancer. J Clin Oncol 16: 434–440PubMedGoogle Scholar
  14. 14.
    de Campos E, Radford J, Steward W, Milroy R, Dougal M, Swindell R, Testa N, Thatcher N (1995) Clinical and in vitro effects of recombinant human erythropoietin in patients receiving intensive chemotherapy for small-cell lung cancer. J Clin Oncol 13: 1623–1631PubMedGoogle Scholar
  15. 15.
    ten Bokkel Huinink WW, de Swart CA, van Toorn DW, Morack G, Breed WP, Hillen HF, van der Hoeven JJ, Reed NS, Fairlamb DJ, Chan SY et al. (1998) Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy. Med Oncol 15: 174–182PubMedGoogle Scholar
  16. 16.
    Osterborg A, Boogaerts MA, Cimino R, Essers U, Holowiecki J, Juliusson G, Jager G, Najman A, Peest D (1996) Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin’s lymphoma — a randomized multicenter study. The European study group of erythropoietin (epoetin beta) treatment in multiple myeloma and non-Hodgkin’s lymphoma. Blood 87: 2675–2682PubMedGoogle Scholar
  17. 17.
    Garton JP, Gertz MA, Witzig TE, Greipp PR, Lust JA, Schroeder G, Kyle RA (1995) Epoetin alfa for the treatment of the anemia of multiple myeloma. A prospective, randomized, placebo-controlled, double-blind trial. Arch Intern Med 155: 2069–2074CrossRefPubMedGoogle Scholar
  18. 18.
    Cascinu S, Del Ferro E, Fedeli A, Ligi M, Alessandroni P, Catalano G (1995) Recombinant human erythropoietin treatment in elderly cancer patients with cisplatin-associated anemia. Oncology 52: 422–426PubMedGoogle Scholar
  19. 19.
    Pawlicki M, Jassem J, Bosze P, Lotan C, Kurteva GP, Siddiqui M, Kosmidis PA, Rigatos GA, Kansu E, Durkovic P et al. (1997) A multicenter study of recombinant human erythropoietin (epoetin alpha) in the management of anemia in cancer patients receiving chemotherapy. Anticancer Drugs 8: 949–957PubMedGoogle Scholar
  20. 20.
    Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B, Epoetin Alfa Study Group (2001) Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19: 2865–2874PubMedGoogle Scholar
  21. 21.
    Osterborg A, Brandberg Y, Molostova V, Iosava G, Abdulkadyrov K, Hedenus M, Messinger D, Epoetin Beta Hematology Study Group (2002) Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol 20: 2486–2494CrossRefPubMedGoogle Scholar
  22. 22.
    Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S (1997) Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 15: 1218–1234PubMedGoogle Scholar
  23. 23.
    Demetri GD, Kris M, Wade J, Degos L, Cella D (1998) Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 16: 3412–3425PubMedGoogle Scholar
  24. 24.
    Ludwig H, Rai K, Blade J, Dammacco F, Degos L, Itri L, Kyle R, Liso V, Littlewood TJ, Mandelli F et al. (2002) Management of disease-related anemia in patients with multiple myeloma or chronic lymphocytic leukemia: Epoetin treatment recommendations. Hematol J 3: 121–130CrossRefPubMedGoogle Scholar
  25. 25.
    Abels RI (1992) Recombinant human erythropoietin in the treatment of the anaemia of cancer. Acta Haematol 87Suppl 1: 4–11PubMedGoogle Scholar
  26. 26.
    Case DC Jr Bukowski RM, Carey RW, Fishkin EH, Henry DH, Jacobson RJ, Jones SE, Keller AM, Kugler JW, Nichols CR (1993) Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. J Natl Cancer Inst 85: 801–806PubMedGoogle Scholar
  27. 27.
    Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhorn LH (2001) Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 19: 2875–2882PubMedGoogle Scholar
  28. 28.
    Del Mastro L, Venturini M, Lionetto R, Garrone O, Melioli G, Pasquetti W, Sertoli MR, Bertelli G, Canavese G, Costantini M et al. (1997) Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia. J Clin Oncol 15: 2715–2721PubMedGoogle Scholar
  29. 29.
    Vansteenkiste J, Pirker R, Massuti B, Barata F, Font A, Fiegl M, Siena S, Gateley J, Tomita D, Colowick AB et al. (2002) Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 94: 1211–1220PubMedGoogle Scholar
  30. 30.
    Seidenfeld J, Piper M, Flamm C, Hasselblad V, Armitage JO, Bennett CL, Gordon MS, Lichtin AE, Wade JL 3rd Woolf S et al. (2001) Epoetin treatment of anemia associated with cancer therapy: A systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst 93: 1204–1214CrossRefPubMedGoogle Scholar
  31. 31.
    Rizzo JD, Lichtin AE, Woolf SH, Seidenfeld J, Bennett CL, Cella D, Djulbegovic B, Goode MJ, Jakubowski AA, Lee SJ et al. (2002) Use of epoetin in patients with cancer: Evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American society of hematology. J Clin Oncol 20: 4083–4107CrossRefPubMedGoogle Scholar
  32. 32.
    Glaspy JA, Jadeja JS, Justice G, Kessler J, Richards D, Schwartzberg L, Tchekmedyian NS, Armstrong S, O’Byrne J, Rossi G et al. (2002) Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. Br J Cancer 87: 268–276CrossRefPubMedGoogle Scholar
  33. 33.
    Hedenus M, Hansen S, Taylor K, Arthur C, Emmerich B, Dewey C, Watson D, Rossi G, Osterborg A, The Darbepoetin alfa 990114 Study Group (2002) Randomized, dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies. Br J Haematol 119: 79–86CrossRefPubMedGoogle Scholar
  34. 34.
    Vogelzang NJ, Breitbart W, Cella D, Curt GA, Groopman JE, Horning SJ, Itri LM, Johnson DH, Scherr SL, Portenoy RK (1997) Patient, caregiver, and oncologist perceptions of cancer-related fatigue: Results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol 34: 4–12PubMedGoogle Scholar
  35. 35.
    Curt GA (2000) Cancer-related fatigue. The next clinical challenge. Oncology 15: 7–11Google Scholar
  36. 36.
    Curt GA, Breitbart W, Cella D, Groopman JE, Horning SJ, Itri LM, Johnson DH, Miaskowski C, Scherr SL, Portenoy RK et al. (2000) Impact of cancer-related fatigue on the lives of patients: New findings from the fatigue coalition. Oncologist 5: 353–360PubMedGoogle Scholar
  37. 37.
    Crawford J, Cella D, Cleeland CS, Cremieux PY, Demetri GD, Sarokhan BJ, Slavin MB, Glaspy JA (2002) Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 95: 888–895CrossRefPubMedGoogle Scholar
  38. 38.
    Levin NW (1992) Quality of life and hematocrit level. Am J Kidney Dis 20: 16–20PubMedGoogle Scholar
  39. 39.
    Evans RW (1991) Recombinant human erythropoietin and the quality of life of end-stage renal disease patients: A comparative analysis. Am J Kidney Dis 18: 62–70PubMedGoogle Scholar
  40. 40.
    Wolcott DL, Marsh JT, La Rue A, Carr C, Nissenson AR (1989) Recombinant human erythropoietin treatment may improve quality of life and cognitive function in chronic hemodialysis patients. Am J Kidney Dis 14: 478–485PubMedGoogle Scholar
  41. 41.
    Delano BG (1989) Improvements in quality of life following treatment with r-HuEPO in anemic hemodialysis patients. Am J Kidney Dis 14: 14–18PubMedGoogle Scholar
  42. 42.
    Beusterien KM, Nissenson AR, Port FK, Kelly M, Steinwald B, Ware JE Jr, (1996) The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients. J Am Soc Nephrol 7: 763–773PubMedGoogle Scholar
  43. 43.
    Barany P, Pettersson E, Konarski-Svensson JK (1993) Long-term effects on quality of life in haemodialysis patients of correction of anaemia with erythropoietin. Nephrol Dial Transplant 8: 426–432PubMedGoogle Scholar
  44. 44.
    Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P, Michaud P, Papo T, Ugo V, Teyssandier I et al. (2002) Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 346: 469–475CrossRefPubMedGoogle Scholar
  45. 45.
    Falkson CI, Keren-Rosenberg S, Uys A, Falkson G, Stevens K, Vermaak WJ (1994) Recombinant human erythropoietin in the treatment of cancer-related anaemia. Oncology 51: 497–501PubMedGoogle Scholar
  46. 46.
    Kasper C, Terhaar A, Fossa A, Welt A, Seeber S, Nowrousian MR (1997) Recombinant human erythropoietin in the treatment of cancer-related anaemia. Eur J Haematol 58: 251–256PubMedGoogle Scholar
  47. 47.
    Braga M, Gianotti L, Vignali A, Gentilini O, Servida P, Bordignon C, Di Carlo V (1995) Evaluation of recombinant human erythropoietin to facilitate autologous blood donation before surgery in anaemic patients with cancer of the gastrointestinal tract. Br J Surg 82: 1637–1640PubMedGoogle Scholar
  48. 48.
    Braga M, Gianotti L, Gentilini O, Vignali A, Di Carlo V (1997) Erythropoietic response induced by recombinant human erythropoietin in anemic cancer patients candidate to major abdominal surgery. Hepatogastroenterology 44: 685–690PubMedGoogle Scholar
  49. 49.
    Rau B, Schlag PM, Willeke F, Herfarth C, Stephan P, Franke W (1998) Increased autologous blood donation in rectal cancer by recombinant human erythropoietin (rhEPO). Eur J Cancer 34: 992–998CrossRefPubMedGoogle Scholar
  50. 50.
    Smith RE Jr Jaiyesimi IA, Meza LA, Tchekmedyian NS, Chan D, Griffith H, Brosman S, Bukowski R, Murdoch M, Rarick M et al. (2001) Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer. Br J Cancer 84: 24–30CrossRefPubMedGoogle Scholar
  51. 51.
    Stebler C, Tichelli A, Dazzi H, Gratwohl A, Nissen C, Speck B (1990) High-dose recombinant human erythropoietin for treatment of anemia in myelodysplastic syndromes and paroxysmal nocturnal hemoglobinuria: A pilot study. Exp Hematol 18: 1204–1208PubMedGoogle Scholar
  52. 52.
    Bessho M, Jinnai I, Matsuda A, Saito M, Hirashima K (1990) Improvement of anemia by recombinant erythropoietin in patients with myelodysplastic syndromes and aplastic anemia. Int J Cell Cloning 8: 445–458PubMedGoogle Scholar
  53. 53.
    Stein RS, Abels RI, Krantz SB (1991) Pharmacologic doses of recombinant human erythropoietin in the treatment of myelodysplastic syndromes. Blood 78: 1658–1663PubMedGoogle Scholar
  54. 54.
    Hellstrom E, Birgegard G, Lockner D, Helmers C, Ost A, Wide L (1991) Treatment of myelodysplastic syndromes with recombinant human erythropoietin. Eur J Haematol 47: 355–360PubMedGoogle Scholar
  55. 55.
    Casadevall N, Belanger C, Goy A, Varet B, Lang J, Poisson D (1992) High-dose recombinant human erythropoietin administered intravenously for the treatment of anaemia in myelodysplastic syndromes. Acta Haematol 87: 25–27PubMedGoogle Scholar
  56. 56.
    Goy A, Belanger C, Casadevall N, Picard F, Guesnu M, Jaulmes D, Poisson D, Varet B (1993) High doses of intravenous recombinant erythropoietin for the treatment of anaemia in myelodysplastic syndrome. Br J Haematol 84: 232–237PubMedGoogle Scholar
  57. 57.
    Mohr B, Herrmann R, Huhn D (1993) Recombinant human erythropoietin in patients with myelodysplastic syndrome and myelofibrosis. Acta Haematol 90: 65–70PubMedGoogle Scholar
  58. 58.
    Bowen D, Culligan D, Jacobs A (1991) The treatment of anaemia in the myelodysplastic syndromes with recombinant human erythropoietin. Br J Haematol 77: 419–423PubMedGoogle Scholar
  59. 59.
    Rafanelli D, Grossi A, Longo G, Vannucchi AM, Bacci P, Ferrini PR (1992) Recombinant human erythropoietin for treatment of myelodysplastic syndromes. Leukemia 6: 323–327PubMedGoogle Scholar
  60. 60.
    Ghio R, Balleari E, Ballestrero A, Gatti AM, Mareni C, Massa G, Patrone F, Sessarego M, Timitilli S (1993) Subcutaneous recombinant human erythropoietin for the treatment of anemia in myelodysplastic syndromes. Acta Haematol 90: 58–64PubMedGoogle Scholar
  61. 61.
    Aloe Spiriti MA, Petti MC, Latagliata R, Avvisati G, De Gregoris C, Proia S, Fazi P, Jaalouk G, Mancini M, Spadea A et al. (1993) Recombinant human erythropoietin in the treatment of myelodysplastic syndromes. An interim report. Haematologica 78: 123–126PubMedGoogle Scholar
  62. 62.
    Stone RM, Bernstein SH, Demetri G, Facklam DP, Arthur K, Andersen J, Aster JC, Kufe D (1994) Therapy with recombinant human erythropoietin in patients with myelodysplastic syndromes. Leuk Res 18: 769–776PubMedGoogle Scholar
  63. 63.
    Stasi R, Brunetti M, Bussa S, Conforti M, Di Giulio C, Crescenzi A, Terzoli E, Vecchione A, Pagano A (1997) Response to recombinant human erythropoietin in patients with myelodysplastic syndromes. Clin Cancer Res 3: 733–739PubMedGoogle Scholar
  64. 64.
    Hansen PB, Johnsen HE, Hippe E, Hellstrom-Lindberg E, Ralfkiaer E (1993) Recombinant human granulocyte-macrophage colony-stimulating factor plus recombinant human erythropoietin may improve anemia in selected patients with myelodysplastic syndromes. Am J Hematol 44: 229–236PubMedGoogle Scholar
  65. 65.
    Negrin RS, Stein R, Vardiman J, Doherty K, Cornwell J, Krantz S, Greenberg PL (1993) Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin. Blood 82: 737–743PubMedGoogle Scholar
  66. 66.
    Negrin RS, Stein R, Doherty K, Cornwell J, Vardiman J, Krantz S, Greenberg PL (1996) Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: Evidence for in vivo synergy. Blood 87: 4076–4081PubMedGoogle Scholar
  67. 67.
    Runde V, Aul C, Ebert A, Grabenhorst U, Schneider W (1995) Sequential administration of recombinant human granulocyte-macrophage colony-stimulating factor and human erythropoietin for treatment of myelodysplastic syndromes. Eur J Haematol 54: 39–45PubMedGoogle Scholar
  68. 68.
    Imamura M, Kobayashi M, Kobayashi S, Yoshida K, Mikuni C, Ishikawa Y, Matsumoto S, Sakamaki S, Niitsu Y, Hinoda Y et al. (1994) Failure of combination therapy with recombinant granulocyte colony-stimulating factor and erythropoietin in myelodysplastic syndromes. Ann Hematol 68: 163–166CrossRefPubMedGoogle Scholar
  69. 69.
    Anonymous (1998) A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes. Br J Haematol 103: 1070–1074Google Scholar
  70. 70.
    Isnard F, Najman A, Jaar B, Fenaux P, Baillou C, Khoury E, Labopin M, Laporte JP, Woler M, Gorin NC et al. (1994) Efficacy of recombinant human erythropoietin in the treatment of refractory anemias without excess of blasts in myelodysplastic syndromes. Leuk Lymphoma 12: 307–314PubMedGoogle Scholar
  71. 71.
    Di Raimondo F, Longo G, Cacciola E Jr Milone G, Palumbo GA, Cacciola RR, Alessi M, Giustolisi R (1996) A good response rate to recombinant erythropoietin alone may be expected in selected myelodysplastic patients. A preliminary clinical study. Eur J Haematol 56: 7–11PubMedGoogle Scholar
  72. 72.
    Henry D, Glaspy J (1997) Predicting response to epoetin alfa in anemic cancer patients receiving chemorx. Proc Am Soc Clin Oncol 16: 49aGoogle Scholar
  73. 73.
    Beguin Y (1998) Prediction of response to optimize outcome of treatment with erythropoietin. Semin Oncol 25: 27–34PubMedGoogle Scholar
  74. 74.
    Ludwig H, Fritz E (1998) Anemia of cancer patients: Patient selection and patient stratification for epoetin treatment. Semin Oncol 25: 35–38PubMedGoogle Scholar
  75. 75.
    Glaspy JA, Jadeja JS, Justice G, Kessler J, Richards D, Schwartzberg L, Tchekmedyian NS, Armstrong S, O’Byrne J, Rossi G et al. (2002) Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. Br J Cancer 87: 268–276CrossRefPubMedGoogle Scholar
  76. 76.
    Glaspy JA, Jadeja JS, Justice G, Fleishman A, Rossi G, Colowick AB (2003) A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin alfa for the treatment of patients with anemia during chemotherapy for malignant disease. Cancer 97: 1312–1320PubMedGoogle Scholar
  77. 77.
    Glaspy J, Cavill I (1999) Role of iron in optimizing responses of anemic cancer patients to erythropoietin. Oncology (Huntingt) 13: 461–473Google Scholar
  78. 78.
    Fishbane S, Frei GL, Maesaka J (1995) Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 26: 41–46PubMedGoogle Scholar
  79. 79.
    Driver PS (1998) Cost-effectiveness impact of iron dextran on hemodialysis patients’ use of epoetin alfa and blood. Am J Health Syst Pharm 55: s12–S16PubMedGoogle Scholar
  80. 80.
    Macdougall IC, Chandler G, Elston O, Harchowal J (1999) Beneficial effects of adopting an aggressive intravenous iron policy in a hemodialysis unit. Am J Kidney Dis 34: S40–S46PubMedGoogle Scholar
  81. 81.
    Besarab A, Amin N, Ahsan M, Vogel SE, Zazuwa G, Frinak S, Zazra JJ, Anandan JV, Gupta A (2000) Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol 11: 530–538PubMedGoogle Scholar
  82. 82.
    Barosi G, Marchetti M, Liberato NL (1998) Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia. Br J Cancer 78: 781–787PubMedGoogle Scholar
  83. 83.
    Cremieux PY, Finkelstein SN, Berndt ER, Crawford J, Slavin MB (1999) Cost effectiveness, quality-adjusted life-years and supportive care. Recombinant human erythropoietin as a treatment of cancer-associated anaemia. Pharmacoeconomics 16: 459–472CrossRefPubMedGoogle Scholar
  84. 84.
    Kallich JD, Tchekmedyian NS, Damiano AM, Shi J, Black JT, Erder MH (2002) Psychological outcomes associated with anemia-related fatigue in cancer patients. Oncology (Huntingt) 16: 117–124Google Scholar
  85. 85.
    Barnett A (2002) Anemia-related costs for cancer patients. J Managed Care Med 6: 20–27Google Scholar
  86. 86.
    Berndt ER, Crown B, Finkelstein S, Kallich J, Erder H, Lyman G (2002) Labor force activity in cancer patients with anemia. Proc Am Soc Clin Oncol 21: 192bGoogle Scholar
  87. 87.
    Finkelsein S, Berndt E, Crown W, Kallich J, Erder H, Lyman G (2002) Anemia as a pedictor of high cost in recently diagnosed cancer patients. Proc Am Soc Clin Oncol 21: 199bGoogle Scholar
  88. 88.
    Caro JJ, Salas M, Ward A, Goss G (2001) Anemia as an independent prognostic factor for survival in patients with cancer: A systemic, quantitative review. Cancer 91: 2214–2221CrossRefPubMedGoogle Scholar
  89. 89.
    Glaspy JA (2002) The potential for anemia treatment to improve survival in cancer patients. Oncology (Huntingt) 16: 35–40Google Scholar
  90. 90.
    Kallinowski F, Friis RR, Van Roy F, Vaupel P (1990) Oxygenation of tumors derived from ras transformed cells. Adv Exp Med Biol 277: 907–916PubMedGoogle Scholar
  91. 91.
    Kallinowski F, Zander R, Hoeckel M, Vaupel P (1990) Tumor tissue oxygenation as evaluated by computerized-pO2-histography. Int J Radiat Oncol Biol Phys 19: 953–961PubMedGoogle Scholar
  92. 92.
    Vaupel P, Kallinowski F, Okunieff P (1990) Blood flow, oxygen consumption and tissue oxygenation of human tumors. Adv Exp Med Biol 277: 895–905PubMedGoogle Scholar
  93. 93.
    Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW (1997) Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 38: 285–289CrossRefPubMedGoogle Scholar
  94. 94.
    Becker A, Hansgen G, Bloching M, Weigel C, Lautenschlager C, Dunst J (1998) Oxygenation of squamous cell carcinoma of the head and neck: Comparison of primary tumors, neck node metastases, and normal tissue. Int J Radiat Oncol Biol Phys 42: 35–41CrossRefPubMedGoogle Scholar
  95. 95.
    Brizel DM, Dodge RK, Clough RW, Dewhirst MW (1999) Oxygenation of head and neck cancer: Changes during radiotherapy and impact on treatment outcome. Radiother Oncol 53: 113–117CrossRefPubMedGoogle Scholar
  96. 96.
    Grogan M, Thomas GM, Melamed I, Wong FL, Pearcey RG, Joseph PK, Portelance L, Crook J, Jones KD (1999) The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer 86: 1528–1536CrossRefPubMedGoogle Scholar
  97. 97.
    Stadler P, Becker A, Feldmann HJ, Hansgen G, Dunst J, Wurschmidt F, Molls M (1999) Influence of the hypoxic subvolume on the survival of patients with head and neck cancer. Int J Radiat Oncol Biol Phys 44: 749–754CrossRefPubMedGoogle Scholar
  98. 98.
    Becker A, Stadler P, Lavey RS, Hansgen G, Kuhnt T, Lautenschlager C, Feldmann HJ, Molls M, Dunst J (2000) Severe anemia is associated with poor tumor oxygenation in head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 46: 459–466CrossRefPubMedGoogle Scholar
  99. 99.
    Brizel DM, Schroeder T, Scher RL, Walenta S, Clough RW, Dewhirst MW, Mueller-Klieser W (2001) Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer. Int J Radiat Oncol Biol Phys 51: 349–353PubMedGoogle Scholar
  100. 100.
    Glaser CM, Millesi W, Kornek GV, Lang S, Schull B, Watzinger F, Selzer E, Lavey RS (2001) Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys 50: 705–715CrossRefPubMedGoogle Scholar
  101. 101.
    Teicher BA, Holden SA, al-Achi A, Herman TS (1990) Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSaIIC murine fibrosarcoma. Cancer Res 50: 3339–3344PubMedGoogle Scholar
  102. 102.
    Thews O, Kelleher DK, Vaupel P (1996) In vivo oxygen consumption rate of DS sarcoma cells on inhibition of DNA synthesis. Cancer Res 56: 2009–2012PubMedGoogle Scholar
  103. 103.
    Jiang BH, Agani F, Passaniti A, Semenza GL (1997) V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: Involvement of HIF-1 in tumor progression. Cancer Res 57: 5328–5335PubMedGoogle Scholar
  104. 104.
    Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, Simons JW (1999) Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 59: 5830–5835PubMedGoogle Scholar
  105. 105.
    Semenza GL (2000) Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Crit Rev Biochem Mol Biol 35: 71–103CrossRefPubMedGoogle Scholar
  106. 106.
    Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, Simons JW, Semenza GL (2000) Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: Implications for tumor angiogenesis and therapeutics. Cancer Res 60: 1541–1545PubMedGoogle Scholar
  107. 107.
    Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL (2001) HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: Novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 21: 3995–4004CrossRefPubMedGoogle Scholar
  108. 108.
    Fukuda R, Hirota K, Fan F, Jung YD, Ellis LM, Semenza GL (2002) Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem 277: 38205–38211PubMedGoogle Scholar
  109. 109.
    Semenza GL (2002) Involvement of hypoxia-inducible factor 1 in human cancer. Intern Med 41: 79–83PubMedGoogle Scholar
  110. 110.
    Dancey J, Zee B, Osoba D, Whitehead M, Lu F, Kaizer L, Latreille J, Pater JL (1997) Quality of life scores: An independent prognostic variable in a general population of cancer patients receiving chemotherapy. The National Cancer Institute of Canada Clinical Trials Group. Qual Life Res 6: 151–158CrossRefPubMedGoogle Scholar
  111. 111.
    Littlewood TJ (2001) The impact of hemoglobin levels on treatment outcomes in patients with cancer. Semin Oncol 28: 49–53CrossRefPubMedGoogle Scholar
  112. 112.
    Jumbe NL (2002) Erythropoietic agents as neurotherapeutic agents: What barriers exist? Oncology (Huntingt) 16: 91–107Google Scholar
  113. 113.
    Brines M (2002) What evidence supports use of erythropoietin as a novel neurotherapeutic? Oncology (Huntingt) 16: 79–89Google Scholar
  114. 114.
    Brines ML, Ghezzi P, Keenan S, Agnello D, de Lanerolle NC, Cerami C, Itri LM, Cerami A (2000) Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 97: 10526–10531CrossRefPubMedGoogle Scholar
  115. 115.
    Brezden CB, Phillips KA, Abdolell M, Bunston T, Tannock IF (2000) Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 18: 2695–2701PubMedGoogle Scholar

Copyright information

© Birkhäuser Verlag/Switzerland 2003

Authors and Affiliations

  • John Glaspy
    • 1
  1. 1.Division of Hematology/OncologyUCLA School of MedicineLos AngelesUSA

Personalised recommendations